Pilot clinical trial of 5-[125I]iodo-2′-deoxyuridine in the treatment of colorectal cancer metastatic to the liver

Journal of Nuclear Medicine

Volumn 37, Issue 4 SUPPL., 1996, Pages

  Macapinlac, Homer A ^a   Kemeny, Nancy ^b   Daghighian, Farhad ^b   Finn, Ronald ^b   Zhang, Jiaju ^b   Humm, John ^b   Squire, Olivia ^b   Larson, Steven M ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

Hepatic infusion; Iododeoxyuridine, colorectal cancer

Indexed keywords

IDOXURIDINE; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COLORECTAL TUMOR; HEPATIC ARTERY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; PATHOLOGY; PILOT STUDY; RADIATION DOSE; RADIOGRAPHY; SCINTISCANNING; TISSUE DISTRIBUTION;

ADULT; AGED; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL NEOPLASMS; HEPATIC ARTERY; HUMANS; IDOXURIDINE; INFUSIONS, INTRA-ARTERIAL; IODINE RADIOISOTOPES; LIVER NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; RADIOTHERAPY DOSAGE; TISSUE DISTRIBUTION;

EID: 0030115746     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Eidinoff ML, Cheong L, Rich MA. Incorporation of unnatural pyrimidine bases into deoxyribonucleic acid of mammalian cells. Science 1959;129:1550-1551.
2. Prusoff WH. Incorporation of iododeoxyuridine, an analog of thymidine, into mammalian deoxyribonucleic acid [Abstract]. Fed Proc 1959;18:305.
3. Krueger RC, Gitlin D, Commerford SL, Stein J, Hughes WL. Iododeoxyuridine (IDU) as a tracer of DNA metabolism in vivo [Abstract]. Fed Proc 1960;19:307.
4. Xeros N. Deoxyriboside control and synchronization of mitosis. Nature 1962;194: 682-683.
5. Kufe DW, Egan EM, Rosowsky A, Ensminger W, Frei E III. Thymidine arrest and synchrony of cellular growth in vivo. Cancer Treat Rep 1980;64:1307-1317.
6. Mathias AP, Fischer GA, Prusoff WH. Inhibition of the growth of mouse leukemia cells in culture by 5-iododeoxyuridine. Biochim Biophys Acta 1959;36:560-561.
7. Calabresi P, Cardoso SS, Finch SC, et al. Initial clinical studies with 5-iodo-2′-deoxyuridine. Cancer Res 1961;21:550-559.
8. Lee SS, Giovanella BC, Stehlin JS Jr. Effect of excess thymidine on the growth of human melanoma cells transplanted in thymus deficient nude mice. Cancer Lett 1977;3:209-214.
9. Howell SB, Chu B, Mendelsohn J, Carson DA, Kung FH, Seegmiller JE. Thymidine as a chemotherapeutic agent: pharmacologic, cytokinetic, and biochemical studies in a patient with T-cell acute lymphocytic leukemia. J Natl Cancer Inst 1980;65:277-284.
10. Bruno S, Poster DS, Bono VH Jr, Macdonald JS, Kubota TT. High-dose thymidine in clinical oncology. Cancer Treat Rep 1981;65:57-63.
11. Djordjevic B, Szybalski W. Genetics of human cell lines. III. Incorporation of 5-bromo and 5-iododeoxyuridine into the deoxyribonucleic acid of human cells and its effect on radiation sensitivity. J Exp Med 1960;112:509-531.
12. Kinsella TJ, Collins J, Rowland J, et al. Pharmacology and phase I/II study of continuous intravenous infusions of iododeoxyuridine and hyperfractionated radiotherapy in patients with glioblastoma multiforme. J Clin Oncol 1988;6:871-879.
13. Lawrence TS, Davis MA, Maybaum J, Stetson PL, Ensminger WD. The dependence of halogenated pyrimidine incorporation and radiosensitization on the duration of drug exposure. Int J Radiat Oncol Biol Phys 1990;18:1393-1398.
14. Sondak V, Lawrence T, Ensminger W, Change A. Preoperative IUdR and radiation for soft tissue sarcomas: preliminary results and normal tissue IUdR-incorporation data [Abstract]. Proc Am Soc Clin Oncol 1990;9:A1228.
15. Watanabe KA, Reichman U, Hirota K, Lopez C, Fox JJ. Nucleosides. 110. Synthesis and antiherpes virus activity of some 2′-fluoro-2′-deoxyarabinofuranosylpyrimidine nucleosides. J Med Chem 1979;22:21-24.
16. Watanabe KA, Su T-L, Klein RS, et al. Nucleosides. 123. Synthesis of antiviral nucleosides: 5-substituted 1-(2-deoxy-2-halogeno-β-D-arabinofuranosyl)cytosines and -uracils. Some structure-activity relationships. J Med Chem 1983;26:152-156.
17. 131I in the mouse and rat. Cancer Res 1961;21:345-352.
18. 125I-iododeoxy-uridine. J Natl Cancer Inst 1969;43:763-773.
19. Dethlefsen L. Incorporation of 125-iodine-labelcd 5-iodo-2′-deoxyuridine into the DNA of mouse mammary tumors. In: Fry RJM, ed. Normal and malignant cell growth. New York: Springer-Verlag; 1969:186-201.
20. 131I. Radiat Res 1971;47:94-109.
21. Klecker RW Jr, Jenkins JF, Kinsella TJ, Fine RL, Strong JM, Collins JM. Clinical pharmacology of 5-iodo-2′-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation. Clin Pharmacol Ther 1985;38:45-51.
22. 125IUdR in mammalian cells: implications of localized energy deposition by Auger processes. Radiat Res 1987;109:78-89.
23. Tjuvajcv JG, Macapinlac HA, Daghighian F, et al. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. J Nucl Med 1994:35;1407-1417.
24. Calabresi P, Finch SC, Cardoso SS, Welch AD. Preliminary clinical experiences with 5-iododeoxyuridine [Abstract]. Proc Am Assoc Cancer Res 1960;3:99.
25. Welch AD, Jaffe JJ, Cardoso SS, et al. Studies on the pharmacology of 5-iododeoxyuridine in animals and man [Abstract]. Proc Am Assoc Cancer Res 1960;3:161.
26. Kriss J, Revesz L. Quantitative studies of incorporation of exogenous thymidine and 5-bromodeoxyuridine into deoxyribonucleic acid of mammalian cells in vitro. Cancer Res 1961;21:1141-1147.
27. Tjuvajev J, Muraki A, Ginos J, et al. Iododeoxyuridine uptake and retention as a measure of tumor growth. J Nucl Med 1993;34:1152-1162.
28. Kemeny N, Seiter K. Hepatic arterial chemotherapy. In: Cohen A, Winawer S, Freidman M, Gunderson L, eds. Cancer of the colon, rectum and anus. New York: McGraw Hill; 1995:831-843.
29. Mariani G, Cei A, Collecchi P, et al. Tumor targeting in vivo and metabolic fate of 5-[iodine-125]iodo-2′-deoxyuridine following intratumoral injection in patients with colorectal cancer. J Nucl Med 1993;34:1175-1183.
30. 123I]iodo-2′-deoxyuridine in patients with liver metastases from colon cancer. J Nucl Biol Med 1993;37:157-158.
31. 125I]iodo-2′-deoxyuridine in rat brain tumors: diagnostic and therapeutic implications in humans. Cancer Res 1990;50:5199-5203.
32. 125I]iododeoxyuridine in the treatment of colorectal cancer metastatic to the liver. II. Pharmacokinetics and dosimetry. J Nucl Med 1996;37(suppl):29S-32S.
33. Scott AM, Macapinlac H, Zhang JJ, et al. Clinical applications of fusion imaging in oncology. Nucl Med Biol 1994;21:775-784.
34. Macapinlac HA, Scott AM, Zhang J, Kalaigian H, Caluser CI, De La Paz RL. Registration of Tl-201 SPECT and PET images with MR images in patients with primary brain tumors [Abstract]. Radiology 1992;185(suppl):234.
35. Scott AM, Macapinlac H, Zhang J, et al. Image registration of SPECT and CT images using an external fiduciary band and three-dimensional surface fitting in metastatic thyroid cancer. J Nucl Med 1995;36:100-103.
36. Scott AM, Macapinlac HA, Divgi CR, et al. Clinical validation of SPECT and CT/MRI image registration in radiolabeled monoclonal antibody studies of colorectal carcinoma. J Nucl Med 1994;35:12:1976-1984.
37. Sgouros G, Chiu S, Pentlow KS, et al. Three-dimensional dosimetry for radioimmunotherapy treatment planning. J Nucl Med 1993;34:1595-1601.
38. Kolbert KS, Sgouros G, Scott AM, et al. Dose-volume histogram representation of patient dose distribution in three-dimensional internal dosimetry. J Nucl Med 1994; 35:123P-124P.
39. Humm JL, Howell RW, Rao DV. Dosimetry of Auger-electron-emitting radionuclides: report no. 3 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 1994;21:1901-1915.
40. 125I in mammalian cells. Radiat Res 1987;111:305-318.
41. Sastry KSR. Biological effects of the Auger emitter iodine-125: a review. Report no. 1 of AAPM Nuclear Medicine Task Group No. 6. Med Phys 1992;19:1361-1370.
42. Quackenbush RC, Shields AF. Local re-utilization of thymidine in normal mouse tissues as measured with iododeoxyuridine. Cell Tissue Kinet 1988;21:381-387.
43. Daghighian F, Pentlow KS, Larson SM, et al. Development of a method to measure kinetics of radiolabelled monoclonal antibody in human tumour with applications to microdosimetry: positron emission tomography studies of iodine-124-labeled 3F8 monoclonal antibody in glioma. Eur J Nucl Med 1993;20:402-409.